Evidence map›Paper›PMID 33541299›Full record

ArticleBMC cancer2021

A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019.

Wacili Da, Zhengbo Tao, Yan Meng, Kaicheng Wen, Siming Zhou, Keda Yang, Lin Tao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Trends of publications on primary sarcomas of bone: A bibliometric analysis.Journal of clinical orthopaedics and trauma · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wacili Da *Department of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Zhengbo Tao *Department of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Yan Meng *Department of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Kaicheng WenDepartment of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Siming ZhouDepartment of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Keda YangDepartment of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China.
Lin TaoDepartment of Orthopedics, The First Hospital of China Medical University, 155 Nan Jing North Street, Shenyang, 110001, Liaoning, China. taolindr@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent decades, the 5-year survival rate of osteosarcoma remains poor, despite the variety of operations, and exploration of drug therapy has become the key to improvement. This study investigates the contribution of different aspects in osteosarcoma and cure, and predicts research hotspots to benefit future clinical outcomes.

methodsThe Web of Science and PubMed databases were queried to collect all relevant publications related to osteosarcoma and cure from 2009 to 2019. These data were imported into CiteSpace and the Online Analysis Platform of Literature Metrology for bibliometric analysis. Bi-clustering was performed on Bibliographic Item co-occurrence Matrix Builder (BICOMB) and gCLUTO to identify hotspots. Additionally, completed clinical trials on osteosarcoma with results past phase II were collated.

resultsA total of 2258 publications were identified in osteosarcoma and cure from 2009 to 2019. China has the largest number of publications (38.49%), followed by the United States (23.03%) with the greatest impact (centrality = 0.44). The centrality of most institutions is < 0.1, and Central South University and Texas MD Anderson Cancer Center possess the highest average citation rates of 3.25 and 2.87. BMC cancer has the highest average citation rate of 3.26 in 772 journals. Four authors (Picci P, Gorlick R, Bielack SS and Bacci G) made the best contributions. We also identified eight hotspots and collected 41 clinical trials related to drug research on osteosarcoma.

conclusionsThe urgent need exists to strengthen global academic exchanges. Overcoming multidrug resistance in osteosarcoma is the focus of past, present and future investigations. Transformation of the metastasis pattern, microenvironment genetics mechanism, alternative methods of systemic chemotherapy and exploration of traditional Chinese medicine is expected to contribute to a new upsurge of research.

Indexed as

BibliometricsBiomedical ResearchDatabases, FactualBone NeoplasmsHumansOsteosarcomaPrognosisSurvival RateTime FactorsBibliometric analysisCo-word biclustering analysisCureHotspotsOsteosarcoma

Identifiers

PMID33541299
PMCPMC7863524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.